O varian neoplasms consist of several histopathologic entities, and treatment depends on the specific tumor type. Epithelial ovarian cancer comprises most malignant ovarian neoplasms (∼ 80%) 1 ; however, other less-common pathologic subtypes must
Search Results
Robert J. Morgan Jr., Ronald D. Alvarez, Deborah K. Armstrong, Barry Boston, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi J. Gray, Perry W. Grigsby, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Russell J. Schilder, Julian C. Schink, Nelson Teng, and Theresa L. Werner
Ernest S. Han and Mark Wakabayashi
M ore than 21,000 women are estimated to be diagnosed with epithelial ovarian cancer in the United States in 2010, and an estimated 13,850 will die of the disease. 1 Of all gynecologic cancers, ovarian cancer is the most common cause of death. 1
Maurie Markman
to help oncologists determine the statistically defined likelihood the patient will experience a more- or less-favorable outcome (prognostic testing). In ovarian cancer, validated and useful prognostic tests include tumor grade, surgical stage, volume
Robert J. Morgan Jr, Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Kian Behbakht, Lee-may Chen, Larry Copeland, Marta Ann Crispens, Maria DeRosa, Oliver Dorigo, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Sanja Percac-Lima, Mario Pineda, Steven C. Plaxe, Matthew A. Powell, Elena Ratner, Steven W. Remmenga, Peter G. Rose, Paul Sabbatini, Joseph T. Santoso, Theresa L. Werner, Jennifer Burns, and Miranda Hughes
Ovarian neoplasms consist of several histopathologic entities; treatment depends on the specific tumor type. 1 Epithelial ovarian cancer comprises the majority of malignant ovarian neoplasms (about 90%) 2 – 4 ; however, other less common pathologic
Deborah K. Armstrong
Most patients with ovarian cancer are diagnosed with advanced-stage cancer. Debulking surgery followed by chemotherapy is recommended. The standard front-line regimen is 6 cycles of paclitaxel plus carboplatin, with docetaxel a reasonable
Mark T. Wakabayashi, Paul S. Lin, and Amy A. Hakim
Edited by Kerrin G. Robinson
E . Cancer statistics, 2008 . CA Cancer J Clin 2008 ; 58 : 71 – 96 . 2. Ozols RF Rubin SC Thomas GM . Epithelial ovarian cancer . In: Hoskins WJ, Perez CA, Young RC, et al., eds . Principles and Practice of Gynecologic Oncology. 4th
Deborah K. Armstrong
The NCCN Guidelines for Ovarian Cancer include recommendations for a broad range of histologic subtypes of this malignancy, and recommendations for use of oral poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors. As maintenance therapy
Joyce Liu and Ursula Matulonis
. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer . N Engl J Med 1996 ; 334 : 1 – 6 . 3. Ozols RF Bundy BN Greer BE . Phase III trial of carboplatin and paclitaxel compared
Robert J. Morgan Jr, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Matthew A. Powell, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Julian C. Schink, Nelson Teng, Theresa L. Werner, Mary A. Dwyer, and Miranda Hughes
: Integrate into professional practice the updates to NCCN Guidelines for Ovarian Cancer Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Ovarian Cancer NCCN Categories of Evidence and Consensus Category
Christine M. Coticchia, Jiang Yang, and Marsha A. Moses
. van Nagell JR Jr DePriest PD Reedy MB . The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer . Gynecol Oncol 2000 ; 77 : 350 – 356 . 3. Chen DX Schwartz PE Li XG . Evaluation of CA 125
